At the recent American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting, researchers reported that treatment with benralizumab (Fasenra) was noninferior to mepolizumab (Nucala) for ...

LIVERPOOL -- Mortality remains high in granulomatosis with polyangiitis (GPA), but the causes of death tend to change over time, a researcher reported here. During the first year after diagnosis of ...

Granulomatosis with polyangiitis (GPA) is a rare condition where the blood vessels become inflamed GRANULOMATOSIS with polyangiitis is a serious condition that can have life-threatening consequences ...

Granulomatosis with polyangiitis (GPA), previously known as Wegener’s granulomatosis, is a rare and life-threatening disorder that restricts the blood flow to several organs, including the lungs, ...

The FDA has approved an expanded indication of AstraZeneca’s benralizumab (Fasenra) in the US for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA), a rare, ...

Amgen Inc.’s AMGN Japanese partner Kissei Pharmaceutical Co., Ltd. said it has started information-sharing activities in Japan, urging healthcare professionals to carefully evaluate the use of Tavneos ...

Please provide your email address to receive an email when new articles are posted on . After 1 year, 38 out of 56 patients no longer needed oral corticosteroids. The proportion of patients ...

Eosinophilic granulomatosis with polyangiitis (EGPA) is a vasculitis characterized by eosinophilic inflammation. Benralizumab, a monoclonal antibody against the interleukin-5α receptor expressed on ...

A patient with MPA may suffer general symptoms or symptoms localized to the kidney, lungs, digestive tract, nerves, skin or heart. The patient may show initial symptoms of fever, muscle pains and ...

Please provide your email address to receive an email when new articles are posted on . Systemic corticosteroid use decreased with mepolizumab treatment. Mean daily oral corticosteroid use fell by 18% ...